Aura Biosciences Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	2019
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	2019
Net Income	-106.47	-86.92	-76.41	-58.76	-35.25	-22.21	Upgrade
Depreciation & Amortization	1.15	1.22	1.3	1.18	0.83	0.83	Upgrade
Loss (Gain) From Sale of Assets	-	-	0.21	-0.02	0	-	Upgrade
Loss (Gain) From Sale of Investments	-1.89	-4.66	-3.99	-0.53	-	-	Upgrade
Stock-Based Compensation	13.97	11.72	8.77	6.41	2.31	0.74	Upgrade
Other Operating Activities	1.54	1.47	1.84	0.97	0.02	-0	Upgrade
Change in Accounts Payable	-0.11	0.48	-1.04	0.34	1.05	-1.72	Upgrade
Change in Other Net Operating Assets	3.58	-3.12	5.48	-4.19	-1.37	-1.96	Upgrade
Operating Cash Flow	-88.23	-79.81	-63.85	-54.6	-32.41	-24.32	Upgrade
Capital Expenditures	-0.57	-1.25	-0.71	-1.09	-2.13	-0.77	Upgrade
Investment in Securities	36.04	70.07	-113.25	-66.78	-	-	Upgrade
Investing Cash Flow	35.47	68.82	-113.96	-67.87	-2.13	-0.77	Upgrade
Issuance of Common Stock	51.52	1.6	97.29	95.63	79.05	0.16	Upgrade
Other Financing Activities	23.41	-	-	-	-0.02	-0.03	Upgrade
Financing Cash Flow	74.93	1.6	97.29	95.63	166.26	10.04	Upgrade
Net Cash Flow	22.15	-9.39	-80.52	-26.84	131.72	-15.06	Upgrade
Free Cash Flow	-88.8	-81.06	-64.56	-55.7	-34.54	-25.09	Upgrade
Free Cash Flow Per Share	-1.58	-1.63	-1.63	-1.86	-6.69	-68.33	Upgrade
Levered Free Cash Flow	-51.44	-50.17	-39.34	-33.69	-20.52	-16.74	Upgrade
Unlevered Free Cash Flow	-51.44	-50.17	-39.34	-33.69	-20.52	-16.73	Upgrade
Change in Working Capital	3.47	-2.64	4.44	-3.85	-0.32	-3.68	Upgrade

Updated Nov 13, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q